AlphaFold predicted structure
SETD5 · Q9C0A6

Mean pLDDT
46.3/ 100
Very low
1,442 residues
Confidence breakdown
- Very high(≥ 90)8%
- Confident(70–90)8%
- Low(50–70)7%
- Very low(< 50)77%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
SET domain containing 5
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
DDG2P
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownEarly onset or syndromic epilepsy
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedFetal anomalies
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownIntellectual disability
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedSkeletal dysplasia
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedCerebral vascular malformations
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedMonogenic short stature
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedintellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency
hereditary disease
autosomal dominant non-syndromic intellectual disability
Intellectual disability
neurodegenerative disease
neurodevelopmental disorder
developmental disability
KBG syndrome
Neurodevelopmental abnormality
type 2 diabetes mellitus
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Histone-lysine N-methyltransferase SETD5
Chromatin regulator required for brain development: acts as a regulator of RNA elongation rate, thereby regulating neural stem cell (NSC) proliferation and synaptic transmission. May act by mediating trimethylation of 'Lys-36' of histone H3 (H3K36me3), which is essential to allow on-time RNA elongation dynamics. Also monomethylates 'Lys-9' of histone H3 (H3K9me1) in vitro. The relevance of histone methyltransferase activity is however subject to discussion
SETD5 · Q9C0A6

Mean pLDDT
46.3/ 100
Very low
1,442 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0